Introduction: Daratumumab (DARA) is a human anti-CD38 IgG1κ monoclonal antibody that
showed synergistic anti-tumor activity in combination with lenalidomide (LEN) in in vitro …

Methods Patients ineligible for high-dose chemotherapy with autologous stem cell
transplantation due to age≥ 65 years or comorbidities were randomized 1: 1 to Rd±DARA …

Introduction: DARA, a human IgGκ monoclonal antibody targeting CD38, is approved as
monotherapy and in combination with standard-of-care regimens for relapsed/refractory …

Background Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (D-
RVd) in the GRIFFIN study improved the stringent complete response rate by the end of …

Background Lenalidomide plus dexamethasone is a standard treatment for patients with
newly diagnosed multiple myeloma who are ineligible for autologous stem-cell …

The phase 2 GRIFFIN study of daratumumab plus lenalidomide/bortezomib/dexamethasone
(D-RVd) for transplant-eligible, newly diagnosed multiple myeloma included a safety run-in …

The efficacy and favorable safety profile of daratumumab monotherapy in multiple myeloma
(MM) was previously reported. Here, we present an updated pooled analysis of 148 patients …

Background Daratumumab showed encouraging efficacy as monotherapy in patients with
heavily pretreated multiple myeloma in the GEN501 and SIRIUS studies. Here we report a …

Daratumumab in combination with lenalidomide‐dexamethasone (D‐Rd) recently received
FDA approval for the treatment of transplant‐ineligible patients with newly diagnosed …

Triplet regimens, such as lenalidomide, bortezomib, and dexamethasone (RVd) or
thalidomide, bortezomib, and dexamethasone (VTd), are standard induction therapies for …